Ongpipattanakul Chayanid, Nair Satish K
Biochemistry. 2018 Jun 12;57(23):3201-3209. doi: 10.1021/acs.biochem.8b00114. Epub 2018 Mar 27.
Circular peptides have long been sought after as scaffolds for drug design as they demonstrate protein-like properties in the context of small, constrained peptides. Traditional routes toward the production of cyclic peptides rely on synthesis or semisynthetic methods, which restrict their use as platforms for the production of large, structurally diverse chemical libraries. Here, we discuss the biosynthetic routes toward the N-C macrocyclization of linear peptide precursors, specifically, those transformations that are catalyzed by peptidases. While canonical peptidases catalyze the proteolysis of linear peptides, the biosynthetic macrocyclases couple proteolytic cleavage with cyclization to produce macrocyclic compounds. In this Perspective, we explore the different structural features that impart on each of these biosynthetic proteases the distinct ability to perform macrocyclization and focus on their potential use in biotechnology.
环状肽长期以来一直被视作药物设计的支架,因为在小型受限肽的背景下,它们展现出类似蛋白质的特性。传统的环状肽生产途径依赖于合成或半合成方法,这限制了它们作为生产大型、结构多样的化学文库平台的应用。在此,我们讨论线性肽前体N-C大环化的生物合成途径,具体而言,是那些由肽酶催化的转化反应。虽然典型的肽酶催化线性肽的蛋白水解,但生物合成大环化酶将蛋白水解切割与环化反应相结合以产生大环化合物。在这篇观点文章中,我们探究赋予这些生物合成蛋白酶各自独特大环化能力的不同结构特征,并关注它们在生物技术中的潜在用途。